Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer This randomized phase Ib ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results